Nirmatrelvir and Ritonavir Combination in COVID-19 Patients With Advanced Chronic Kidney Disease

Clin Infect Dis. 2024 Sep 26;79(3):798-800. doi: 10.1093/cid/ciad785.

Emmanuel Lafont¹, Damien Blez², Marc-Antoine Bildan³, David Veyer^{4

5

6}, Hélène Péré^{4

5

6}, Julien Puech⁴, Benjamin Kably^{7

8}, Geoffrey Cheminet¹, Jacques Pouchot^{1

6}, Eric Thervet^{6

9}, Gilles Peytavin^{6

10}, Helene Lazareth^{6

9}

¹ Department of Internal Medicine, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
² Bacteriology Laboratory, Microbiology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
³ Pharmacology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁴ Virology Laboratory, Microbiology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
⁵ Unité mixte de recherche 1137, Infections Antimicrobials Modelling Evolution, Université Paris Cité, Paris, France.
⁶ Université Paris Cité, Paris, France.
⁷ Pharmacology Unit and Departement Medicaux Universitaire BIOPHYGEN, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
⁸ Inserm Paris Cardiovascular Research Center UMRS970, Paris, France.
⁹ Nephrology Department, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
¹⁰ Pharmacology Department, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France.

No abstract available

Publication types